FRIDAY, SEPTEMBER 10th, 2021

All times in Central European Summer Time (CEST)

 

13:00-14:00

14:00-14:05

 

14:05 - 15:35

POSTER SESSION: meet the poster presenter

Announcement: MDS/EHDN teaching course

Michael Orth

PLENARY SESSION III: Clinical Trial Session*

*This Session involves content created by Industry (in agreement with the EHDN Program Committee).
Different Pharma industries have the opportunity to present their current trials, results and upcoming
projects.

 

15:35-15:45

BREAK  

15:45-16:30

16:30-16:45

PANEL DISCUSSION

With the Speakers from Plenary Session III

BREAK

 

16:45 - 17:45

PARALLEL SESSIONS

 

 

Neuro-Development

Chaired by: Sandrine Humbert and Silvia Gines

1. Huntington’s disease alters cortical
development in mouse and human (20 min)

Monia Barnat

2. Pediatric onset Huntington disease: neuro
developmental delay or early neurodegeneration? (20 min)

Ferdinando Squitieri

3. Specific developmental alterations of striatal
subpopulations in Huntington’s disease (20 min)

Josep Canals

Multidisciplinary care

Chaired by: Marleen van Walsem
and Ruth Veenhuizen

1. Introduction (5 min): Multidisciplinary care and treatment: focus on care in advanced stages: challenges and approaches for managing

2. Challenges and practise-based approaches in professional advanced care (15 min)

Marleen van Walsem

3. Patients with Huntington's disease living in a nursing home: characteristics, functioning, and gender differences (15 min)

Ruth Veenhuizen

4. Passivities of daily living (15 min)

Manon van Kampen

5. Discussion (10 min)

17:45 - 18:45

SHORT COMMUNICATIONS II

Chaired by: Ahmad Aziz and Maria Björkqvist

1. Fronto-Striatal Circuits for Cognitive Flexibility in far from Onset Huntington’s Disease: Evidence from the Young Adult Study

Christelle Langley

2. Mutation-Related Apparent Myelin, not Axon Density, Drives White Matter Pathology in Premanifest Huntington’s Disease: Evidence from in Vivo Ultra-Strong Gradient MRI

Chiara Casella

3. A Different Depression: Antidepressant Efficacy and Cognitive Mechanisms of Mood Disorder in Huntington’s Disease

 Duncan McLauchlan

4. Clinical Translation of Stem Cell Therapies for Huntington’s Disease (HD)

Anne Rosser

5. Triheptanoin is Associated with Clinical Stability and Decreased Caudate Atrophy in HD

Fanny Mochel

 

18:45 - 19:00

 

19:00 - 20:00

ROUND-UP and Goodbye for the day

Hosts Anne Rosser and Jean-Marc Burgunder with Ahmad Aziz and Dina de Sousa

 

POSTER SESSION: meet the poster presenter